JP2020507561A5 - - Google Patents

Download PDF

Info

Publication number
JP2020507561A5
JP2020507561A5 JP2019538396A JP2019538396A JP2020507561A5 JP 2020507561 A5 JP2020507561 A5 JP 2020507561A5 JP 2019538396 A JP2019538396 A JP 2019538396A JP 2019538396 A JP2019538396 A JP 2019538396A JP 2020507561 A5 JP2020507561 A5 JP 2020507561A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019538396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507561A (ja
JP7101684B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/015985 external-priority patent/WO2018140956A1/en
Publication of JP2020507561A publication Critical patent/JP2020507561A/ja
Publication of JP2020507561A5 publication Critical patent/JP2020507561A5/ja
Priority to JP2022107980A priority Critical patent/JP2022153405A/ja
Application granted granted Critical
Publication of JP7101684B2 publication Critical patent/JP7101684B2/ja
Priority to JP2024095141A priority patent/JP2024116321A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019538396A 2017-01-30 2018-01-30 一価の抗プロペルジン抗体および抗体断片 Active JP7101684B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022107980A JP2022153405A (ja) 2017-01-30 2022-07-04 一価の抗プロペルジン抗体および抗体断片
JP2024095141A JP2024116321A (ja) 2017-01-30 2024-06-12 一価の抗プロペルジン抗体および抗体断片

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762452187P 2017-01-30 2017-01-30
US62/452,187 2017-01-30
PCT/US2018/015985 WO2018140956A1 (en) 2017-01-30 2018-01-30 Monovalent anti-properdin antibodies and antibody fragments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022107980A Division JP2022153405A (ja) 2017-01-30 2022-07-04 一価の抗プロペルジン抗体および抗体断片

Publications (3)

Publication Number Publication Date
JP2020507561A JP2020507561A (ja) 2020-03-12
JP2020507561A5 true JP2020507561A5 (https=) 2021-03-04
JP7101684B2 JP7101684B2 (ja) 2022-07-15

Family

ID=62978808

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019538396A Active JP7101684B2 (ja) 2017-01-30 2018-01-30 一価の抗プロペルジン抗体および抗体断片
JP2022107980A Pending JP2022153405A (ja) 2017-01-30 2022-07-04 一価の抗プロペルジン抗体および抗体断片
JP2024095141A Pending JP2024116321A (ja) 2017-01-30 2024-06-12 一価の抗プロペルジン抗体および抗体断片

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022107980A Pending JP2022153405A (ja) 2017-01-30 2022-07-04 一価の抗プロペルジン抗体および抗体断片
JP2024095141A Pending JP2024116321A (ja) 2017-01-30 2024-06-12 一価の抗プロペルジン抗体および抗体断片

Country Status (12)

Country Link
US (3) US11198725B2 (https=)
EP (1) EP3573661A4 (https=)
JP (3) JP7101684B2 (https=)
KR (2) KR20230173731A (https=)
CN (2) CN118184777A (https=)
AU (2) AU2018212012B2 (https=)
BR (1) BR112019014652A2 (https=)
CA (1) CA3049806A1 (https=)
CO (1) CO2019007686A2 (https=)
IL (2) IL309890A (https=)
MX (3) MX2019008827A (https=)
WO (1) WO2018140956A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118184777A (zh) * 2017-01-30 2024-06-14 亚力兄制药公司 单价抗备解素抗体及抗体片段
BR112019028269A2 (pt) 2017-07-11 2020-07-14 Alexion Pharmaceuticals, Inc. polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
JP7222075B2 (ja) * 2018-09-13 2023-02-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド C3糸球体症のモデルとしての補体因子h遺伝子ノックアウトラット
CN115003694A (zh) * 2020-01-08 2022-09-02 载度思生命科学有限公司 抗备解素抗体及其制备
WO2022066774A1 (en) 2020-09-23 2022-03-31 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
CN114432449B (zh) * 2020-10-30 2024-05-28 广州市妇女儿童医疗中心 用于抑制mhc-i和/或ii信号通路的试剂在治疗胆道闭锁中的应用
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof
WO2024108529A1 (en) * 2022-11-25 2024-05-30 Linno Pharmaceuticals Inc. Properdin binding protein and use thereof
TW202413435A (zh) * 2022-08-05 2024-04-01 美商艾力克森製藥公司 融合蛋白的藥物組成物及其使用方法
TW202417490A (zh) * 2022-08-31 2024-05-01 美商艾力克森製藥公司 用於治療鐮狀細胞病的融合多肽之劑量及投與
EP4395825A4 (en) * 2022-11-25 2025-08-20 Linno Pharmaceuticals Inc PROPERDIN-BINDING PROTEIN AND ITS USE
CN120399074B (zh) * 2023-06-02 2025-12-30 安徽金百奥生物科技有限公司 一种与人dr3胞外域高亲和力的纳米抗体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
WO2006081249A2 (en) 2005-01-25 2006-08-03 Cell Therapeutics, Inc. Conjugates of biologically active proteins having a modified in vivo half-life
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP3299027A1 (en) 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US8435512B2 (en) * 2008-03-03 2013-05-07 Novelmed Therapeutics, Inc. Anti-properdin antibodies
NZ597259A (en) 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
US20110172398A1 (en) 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
AU2011224224B2 (en) * 2010-03-10 2015-07-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
EA202092589A3 (ru) 2010-11-08 2021-06-30 Аблинкс Н.В. Cxcr2-связывающие полипептиды
JP6293659B2 (ja) 2011-07-01 2018-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗プロペルジン抗体およびその使用
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
PE20150159A1 (es) * 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p
CN104114187A (zh) * 2011-12-28 2014-10-22 诺沃姆德治疗公司 去糖基化的人类抗体、其融合蛋白质及用途
EP2904014A4 (en) 2012-10-04 2016-09-28 Novelmed Therapeutics Inc FOR ALTERNATIVE PATHS, SPECIFIC ANTIBODIES FOR THE TREATMENT OF HEMOLYTIC DISEASES
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN118184777A (zh) * 2017-01-30 2024-06-14 亚力兄制药公司 单价抗备解素抗体及抗体片段
CN110003335B (zh) * 2019-04-12 2023-07-04 深圳普瑞金生物药业股份有限公司 Cd47单域抗体、核酸及试剂盒

Similar Documents

Publication Publication Date Title
JP2020507561A5 (https=)
JP2022153405A5 (https=)
JP2024116321A5 (https=)
JP2024063213A (ja) 改良された血清アルブミン結合剤
AU2016351710B2 (en) Improved serum albumin-binding immunoglobulin variable domains
JP6529498B2 (ja) EGFRvIIIに対して特異的な抗体結合部位
RU2687588C2 (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
JP2020062036A5 (https=)
JP2019535763A5 (https=)
JP2021514973A5 (https=)
JP2017522903A5 (https=)
JP2015522252A5 (https=)
JP2019505527A5 (https=)
JP2016529229A5 (https=)
JP2019503990A5 (https=)
JP2016512551A5 (https=)
JP2014533239A5 (https=)
RU2018112861A (ru) Стабильные антитела, связывающиеся с несколькими антигенами
JP2018505674A5 (https=)
JP2016527314A5 (https=)
JP2017500018A5 (https=)
JP2016511277A5 (https=)
JP2014509861A (ja) Cd70に対する抗体
RU2016100892A (ru) Антитела против tweakr и их применение
JP2020524661A5 (https=)